Moderna Bears Face Possible Squeeze on Covid Vaccine Results, , on November 11, 2020 at 5:48 pm

Financial News
By
On November 11, 2020
In Financial News
Tags:

(Bloomberg) — Bearish investors are holding on to their short bets on Moderna Inc. even as the biotech’s market value swelled by more than $25 billion this year on optimism its experimental messenger-RNA vaccine will play a part in tamping down the pandemic.Options data suggest the stock is ready for another double-digit swing over the next few weeks and with S3 Partners data showing about $1.84 billion shares shorted, bears might face fresh pain or finally claw back some losses.Moderna “was and is now a short squeeze candidate,” Ihor Dusaniwsky, S3’s managing director of predictive analytics, said in an interview.The company is expected to have an interim early look this month at how effective its shot, mRNA-1273, is at preventing Covid-19. Results on Monday from Pfizer Inc. and BioNTech SE’s vaccine offered both boon and bane to Moderna. The shot set a high bar for the competition as a first look at their late-stage study showed more than 90% effectiveness is preventing symptomatic infections. At the same time, vaccine similarities bode well for Moderna.Options indicate shares could move 16% in either direction by the end of November and 27% if looking further out to Dec. 24. Moderna has soared more than 300% this year. If the stock rallies further, bearish traders may have to buy up the stock to prevent more losses on their short bets. The short sellers have already been feeling the pinch and some cut their losses after the stock reached a peak in July. Short bets around the time topped out at $2.4 billion, according to S3 data.“This has not been a profitable trade for short sellers as they are down $1.27 billion in year-to-date mark-to-market losses, including $209 million” so far in November, Dusaniwsky said. If Moderna’s stock fell by 27%, shortsellers could recoup $486 million of their losses, he said.Moderna remains the largest short bet in the biotech sector, followed by Amgen Inc. and another Covid-tied name, Gilead Sciences Inc.Daytrader EffectStay-at-home daytraders bolster many Covid-19 plays and — for Gilead at least — were quick to step aside once a commercial reality approached. Gilead’s stock peeled off more than 20% since a May 1 clearance for its Covid-19 treatment.While Pfizer and Moderna are leading the pack, there are at least 11 late-stage studies underway including large-scale trials from AstraZeneca Plc and Johnson & Johnson. Moderna shares jumped as much as 9.3% in New York Wednesday to $83.10, the highest since late July.“Given the competitive nature of Covid-19 vaccines (there could be many) and the uncertain duration of pandemic, we believe that the market is already ascribing a substantial amount of value to these vaccines, leaving us cautious on the ultimate opportunity,” JPMorgan analyst Cory Kasimov cautioned clients in a research note after Pfizer and BioNTech results.Infection TriggersFor Moderna’s shot, an interim analysis will be triggered after 53 volunteers from its roughly 40,000-person study come down with a Covid-19 infection. The participants are split between those vaccinated and those getting a placebo, and volunteers will be followed for a safety analysis. A second analysis will occur after 106 infections. That might not take long with new infections accelerating and hitting a record in the U.S.Pfizer’s shot is expected to have a required two months of safety data next week, which — if all turns out well — could get some high-risk individuals vaccinated in December, according to Anthony Fauci, the nation’s top infectious disease expert.While the U.S. has signed Pfizer up for 100 million doses and an option for another 500 million, the country will need more than one vaccine to head off the Covid tide. And Moderna, back in August, signed a 100 million dose deal with the government.Monday’s data from Pfizer grabbed the market’s attention, fueling a stock market rally that faded after investors began to contemplate the distribution logistics and how many vaccine-skeptical Americans will actually take it. And there is yet to be a full picture on safety or how long shots will be effective.(Adds short interest details and commentary starting in second paragraph, updates shares.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.,

Moderna Bears Face Possible Squeeze on Covid Vaccine Results(Bloomberg) — Bearish investors are holding on to their short bets on Moderna Inc. even as the biotech’s market value swelled by more than $25 billion this year on optimism its experimental messenger-RNA vaccine will play a part in tamping down the pandemic.Options data suggest the stock is ready for another double-digit swing over the next few weeks and with S3 Partners data showing about $1.84 billion shares shorted, bears might face fresh pain or finally claw back some losses.Moderna “was and is now a short squeeze candidate,” Ihor Dusaniwsky, S3’s managing director of predictive analytics, said in an interview.The company is expected to have an interim early look this month at how effective its shot, mRNA-1273, is at preventing Covid-19. Results on Monday from Pfizer Inc. and BioNTech SE’s vaccine offered both boon and bane to Moderna. The shot set a high bar for the competition as a first look at their late-stage study showed more than 90% effectiveness is preventing symptomatic infections. At the same time, vaccine similarities bode well for Moderna.Options indicate shares could move 16% in either direction by the end of November and 27% if looking further out to Dec. 24. Moderna has soared more than 300% this year. If the stock rallies further, bearish traders may have to buy up the stock to prevent more losses on their short bets. The short sellers have already been feeling the pinch and some cut their losses after the stock reached a peak in July. Short bets around the time topped out at $2.4 billion, according to S3 data.“This has not been a profitable trade for short sellers as they are down $1.27 billion in year-to-date mark-to-market losses, including $209 million” so far in November, Dusaniwsky said. If Moderna’s stock fell by 27%, shortsellers could recoup $486 million of their losses, he said.Moderna remains the largest short bet in the biotech sector, followed by Amgen Inc. and another Covid-tied name, Gilead Sciences Inc.Daytrader EffectStay-at-home daytraders bolster many Covid-19 plays and — for Gilead at least — were quick to step aside once a commercial reality approached. Gilead’s stock peeled off more than 20% since a May 1 clearance for its Covid-19 treatment.While Pfizer and Moderna are leading the pack, there are at least 11 late-stage studies underway including large-scale trials from AstraZeneca Plc and Johnson & Johnson. Moderna shares jumped as much as 9.3% in New York Wednesday to $83.10, the highest since late July.“Given the competitive nature of Covid-19 vaccines (there could be many) and the uncertain duration of pandemic, we believe that the market is already ascribing a substantial amount of value to these vaccines, leaving us cautious on the ultimate opportunity,” JPMorgan analyst Cory Kasimov cautioned clients in a research note after Pfizer and BioNTech results.Infection TriggersFor Moderna’s shot, an interim analysis will be triggered after 53 volunteers from its roughly 40,000-person study come down with a Covid-19 infection. The participants are split between those vaccinated and those getting a placebo, and volunteers will be followed for a safety analysis. A second analysis will occur after 106 infections. That might not take long with new infections accelerating and hitting a record in the U.S.Pfizer’s shot is expected to have a required two months of safety data next week, which — if all turns out well — could get some high-risk individuals vaccinated in December, according to Anthony Fauci, the nation’s top infectious disease expert.While the U.S. has signed Pfizer up for 100 million doses and an option for another 500 million, the country will need more than one vaccine to head off the Covid tide. And Moderna, back in August, signed a 100 million dose deal with the government.Monday’s data from Pfizer grabbed the market’s attention, fueling a stock market rally that faded after investors began to contemplate the distribution logistics and how many vaccine-skeptical Americans will actually take it. And there is yet to be a full picture on safety or how long shots will be effective.(Adds short interest details and commentary starting in second paragraph, updates shares.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

,

Instant Quote

Enter the Stock Symbol.

Select the Exchange.

Select the Type of Security.

Please enter your First Name.

Please enter your Last Name.

Please enter your phone number.

Please enter your Email Address.

Please enter or select the Total Number of Shares you own.

Please enter or select the Desired Loan Amount you are seeking.

Please select the Loan Purpose.

Please select if you are an Officer/Director.

High West Capital Partners, LLC may only offer certain information to persons who are “Accredited Investors” and/or “Qualified Clients” as those terms are defined under applicable Federal Securities Laws. In order to be an “Accredited Investor” and/or a “Qualified Client”, you must meet the criteria identified in ONE OR MORE of the following categories/paragraphs numbered 1-20 below.

High West Capital Partners, LLC cannot provide you with any information regarding its Loan Programs or Investment Products unless you meet one or more of the following criteria. Furthermore, Foreign nationals who may be exempt from qualifying as a U.S. Accredited Investor are still required to meet the established criteria, in accordance with High West Capital Partners, LLC’s internal lending policies. High West Capital Partners, LLC will not provide information or lend to any individual and/or entity that does not meet one or more of the following criteria:

1) Individual with Net Worth in excess of $1.0 million. A natural person (not an entity) whose net worth, or joint net worth with his or her spouse, at the time of purchase exceeds $1,000,000 USD. (In calculating net worth, you may include your equity in personal property and real estate, including your principal residence, cash, short-term investments, stock and securities. Your inclusion of equity in personal property and real estate should be based on the fair market value of such property less debt secured by such property.)

2) Individual with $200,000 individual Annual Income. A natural person (not an entity) who had individual income of more than $200,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

3) Individual with $300,000 Joint Annual Income. A natural person (not an entity) who had joint income with his or her spouse in excess of $300,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

4) Corporations or Partnerships. A corporation, partnership, or similar entity that has in excess of $5 million of assets and was not formed for the specific purpose of acquiring an interest in the Corporation or Partnership.

5) Revocable Trust. A trust that is revocable by its grantors and each of whose grantors is an Accredited Investor as defined in one or more of the other categories/paragraphs numbered herein.

6) Irrevocable Trust. A trust (other than an ERISA plan) that (a)is not revocable by its grantors, (b) has in excess of $5 million of assets, (c) was not formed for the specific purpose of acquiring an interest, and (d) is directed by a person who has such knowledge and experience in financial and business matters that such person is capable of evaluating the merits and risks of an investment in the Trust.

7) IRA or Similar Benefit Plan. An IRA, Keogh or similar benefit plan that covers only a single natural person who is an Accredited Investor, as defined in one or more of the other categories/paragraphs numbered herein.

8) Participant-Directed Employee Benefit Plan Account. A participant-directed employee benefit plan investing at the direction of, and for the account of, a participant who is an Accredited Investor, as that term is defined in one or more of the other categories/paragraphs numbered herein.

9) Other ERISA Plan. An employee benefit plan within the meaning of Title I of the ERISA Act other than a participant-directed plan with total assets in excess of $5 million or for which investment decisions (including the decision to purchase an interest) are made by a bank, registered investment adviser, savings and loan association, or insurance company.

10) Government Benefit Plan. A plan established and maintained by a state, municipality, or any agency of a state or municipality, for the benefit of its employees, with total assets in excess of $5 million.

11) Non-Profit Entity. An organization described in Section 501(c)(3) of the Internal Revenue Code, as amended, with total assets in excess of $5 million (including endowment, annuity and life income funds), as shown by the organization’s most recent audited financial statements.

12) A bank, as defined in Section 3(a)(2) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

13) A savings and loan association or similar institution, as defined in Section 3(a)(5)(A) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

14) A broker-dealer registered under the Exchange Act.

15) An insurance company, as defined in Section 2(13) of the Securities Act.

16) A “business development company,” as defined in Section 2(a)(48) of the Investment Company Act.

17) A small business investment company licensed under Section 301 (c) or (d) of the Small Business Investment Act of 1958.

18) A “private business development company” as defined in Section 202(a)(22) of the Advisers Act.

19) Executive Officer or Director. A natural person who is an executive officer, director or general partner of the Partnership or the General Partner, and is an Accredited Investor as that term is defined in one or more of the categories/paragraphs numbered herein.

20) Entity Owned Entirely By Accredited Investors. A corporation, partnership, private investment company or similar entity each of whose equity owners is a natural person who is an Accredited Investor, as that term is defined in one or more of the categories/paragraphs numbered herein.

Please read the notice above and check the box below to continue.

Singapore

+65 3105 1295

Taiwan

Coming Soon!

Hong Kong

R91, 3rd Floor,
Eton Tower, 8 Hysan Ave.
Causeway Bay, Hong Kong
+852 3002 4462

Follow Us

Market Coverage